PEAR Therapeutics
-
Pear Therapeutics acquires VR tech for pain treatment
The company is adding several new products to its pipeline, including treatments for chronic pain and migraines, and voice-based biomarkers.
-
Pear, Ironwood have gut instinct for digital therapeutics with new partnership
The companies will evaluate prescription digital therapeutics for patients with gastrointestinal diseases. Pear said it would allow the company to expand beyond its focus on neurological conditions.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Express Script prepares to launch stand-alone digital health formulary in 2020
Express Scripts will offer payers a curated list of technology and software-enabled applications and devices that have been vetted for safety, effectiveness and usability.
-
Digital therapeutics startup Akili Interactive inks deal with Japanese pharma company
In exchange for ceding rights to develop, sell and market Akili’s two lead products in Japan and Taiwan to Shionogi, Akili will receive $20 million upfront and up to $105 million in additional payments dependent on reaching certain development and commercial milestones.
-
San Francisco mental health startup Big Health expands into anxiety
The startup previously developed the Sleepio application, which is targeted at insomnia, and is offered to around 12 million users through partnerships with payers and employers like Boston Medical Center, Comcast and the NHS.
-
More than half of patients willing to use digital therapeutic, study says
The report also found that 56 percent of physicians have brought up the potential for a digital therapy as an option for their patients, and 26 percent have discussed the option after a patient brought it up.
-
Events, Artificial Intelligence
Challenges and opportunities in FDA’s new digital health regulations
A range of companies at the Digital Health showcase in San Francisco discussed how they view the changing regulatory environment within the category of software as a medical device.
-
Opioid addiction app from Novartis and Pear Therapuetics gets FDA nod
The reSET-O prescription mobile application is directed at supporting patients using buprenorphine as a medicinal aid in treatment to overcome opioid addiction.
-
Rock Health: Digital health investing has already surpassed record-breaking 2017
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
For medtech and life science startups, the best course to reimbursement is relative
At the MedCity INVEST conference in Chicago last week, panelists shared insights on what companies need to consider for what can be a complicated pathway to reimbursement.
-
Why investors want healthcare entrepreneurs to develop their business model and economics skills
It’s not enough for a healthcare startup to just have cool technology. To get buy-in from investors, entrepreneurs have to showcase some healthcare economics chops, as well as a solid business model and reimbursement plan.
-
Novartis teams up with Pear Therapeutics to develop digital therapeutics for schizophrenia, MS
Pear Therapeutics Chief Medical Officer Yuri Maricich emphasized that the products Pear is developing with Novartis are intended to do more than support adherence.
-
Healthcare leaders should keep an eye on these 10 innovations in 2018
ECRI Institute has unveiled a list of 10 emerging innovations healthcare leaders should watch this year. A neonatal MRI system, direct-to-consumer genetic testing and VR for pediatric patients are among the topics that made the cut.
-
These 9 companies made it to the FDA’s pilot digital health program (Updated)
The picks span telecom giants to medtech companies but also include smaller companies with novel technologies such as digital therapeutics developer Pear Therapeutics and Tidepool — an open source technology developer to support diabetes management, .
-
Pear Therapeutics gets greenlight from FDA for addiction treatment via digital therapeutic
The FDA’s clearance for the prescribed app, aimed at individuals as part of outpatient therapy for substance use disorders spanning alcohol, cocaine, marijuana, and stimulants, is a major milestone for digital therapeutics and suggests more companies will seek FDA approval.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
